Medication & prices

Mounjaro activates both the GIP and GLP-1 receptors. Through this dual mechanism, it improves glucose metabolism, reduces appetite, and supports weight loss in adults with type 2 diabetes or obesity. The rates listed below are monthly prices, depending on the selected bundle duration and dosage.

Wegovy is used for obesity or overweight. Semaglutide, the active substance in Wegovy, is a GLP-1 receptor agonist that mimics the action of the body’s natural hormone GLP-1. It helps regulate blood sugar levels, slows gastric emptying, and reduces appetite. The rates listed below are monthly prices, depending on the selected bundle duration and dosage.

Ozempic is used for type 2 diabetes. Semaglutide, the active substance in Ozempic, is a GLP-1 receptor agonist that mimics the action of the body’s natural hormone GLP-1. It helps regulate blood sugar levels, slows gastric emptying, and reduces appetite. The rates listed below are monthly prices, depending on the selected bundle duration and dosage.

Saxenda is a GLP-1 agonist that is injected daily. It reduces hunger and increases feelings of fullness, supporting weight loss in adults with overweight or obesity. The rates listed below are monthly prices, depending on the selected bundle duration.

Rybelsus contains the same active substance as Wegovy and Ozempic, namely semaglutide, but is taken in tablet form. It is only approved for the treatment of adults with type 2 diabetes mellitus when diet and exercise are insufficient to control blood sugar levels. The rates listed below are monthly prices, depending on the selected bundle duration.

Mysimba (active substances: naltrexone and bupropion) is an orally administered medication used to help adults with obesity lose weight and maintain weight loss. This medicine works on areas of the brain involved in the regulation of food intake and energy expenditure.

Zepbound is a prescription medication containing the active substance tirzepatide, used for weight management. The medication is approved by the FDA in the United States but will not be introduced to the Dutch market. In the Netherlands, Mounjaro is prescribed instead.

Retatrutide is a new medication currently being studied for its potential effectiveness in the treatment of obesity and type 2 diabetes. Manufacturer Eli Lilly and Company is still in the clinical trial phase for this substance, but preliminary results indicate a positive effect.

Orforglipron is a new medication currently being investigated for the treatment of obesity and type 2 diabetes. It is developed by Eli Lilly and Company and belongs to the class of GLP-1 receptor agonists.